vidarabine phosphate has been researched along with Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (33.33) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeavons, M; Lehouritis, P; McCarthy, FO; Stanton, M; Tangney, M | 1 |
| Bagley, RG; Crawford, J; Krumbholz, R; Kurtzberg, LS; Lovett, D; Roth, S; Rouleau, C; Schmid, S; Teicher, BA; Yao, M | 1 |
| Clark, G; Hersh, M; Hutton, JJ; Kuhn, J; Phillips, J; Von Hoff, DD | 1 |
| Boldt, DH; Hersh, M; Kuhn, JG; Von Hoff, DD | 1 |
| Cabanillas, F; Dimopoulos, M; Gandhi, V; Gregoire, V; Kantarjian, H; Keating, MJ; McLaughlin, P; O'Brien, S; Robertson, LE; Yang, LY | 1 |
| Grever, MR; Malspeis, L; Staubus, AE; Young, D | 1 |
| Von Hoff, DD | 1 |
| Balcerzak, S; Grever, M; Kraut, E; Leiby, J; Malspeis, L; Metz, E; Neidhart, J | 1 |
| Cheson, BD; Chun, HG; Leyland-Jones, B | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Casper, ES; Kelson, D; Mittelman, A; Young, CW | 1 |
| Grever, MR; Leiby, JM; Malspeis, L; Neidhart, JA; Staubus, AE | 1 |
4 review(s) available for vidarabine phosphate and Neoplasms
| Article | Year |
|---|---|
New initiatives with fludarabine monophosphate in hematologic malignancies.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Hematologic Diseases; Humans; Neoplasms; Remission Induction; Vidarabine Phosphate | 1993 |
Phase I clinical trials with fludarabine phosphate.
Topics: Animals; Antimetabolites, Antineoplastic; Child; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Humans; Neoplasms; Vidarabine Phosphate | 1990 |
Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Topics: Antimetabolites, Antineoplastic; Humans; Leukemia; Neoplasms; Vidarabine Phosphate | 1991 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
2 trial(s) available for vidarabine phosphate and Neoplasms
| Article | Year |
|---|---|
A comprehensive phase I and II clinical investigation of fludarabine phosphate.
Topics: Adult; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Evaluation; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Neoplasms; Vidarabine Phosphate | 1990 |
Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.
Topics: Antimetabolites, Antineoplastic; Humans; Leukemia; Neoplasms; Vidarabine Phosphate | 1991 |
7 other study(ies) available for vidarabine phosphate and Neoplasms
| Article | Year |
|---|---|
Activation of multiple chemotherapeutic prodrugs by the natural enzymolome of tumour-localised probiotic bacteria.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Aziridines; Bacterial Proteins; Bifidobacterium; Cell Line, Tumor; Drug Delivery Systems; Enzymes; Escherichia coli; Female; Lactobacillus; Lactococcus; Mice, Inbred BALB C; Neoplasms; Probiotics; Prodrugs; Tumor Burden; Vidarabine Phosphate | 2016 |
Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.
Topics: Adenine Nucleotides; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Bone Marrow Cells; Cells, Cultured; Cladribine; Clofarabine; Granulocyte-Macrophage Progenitor Cells; HT29 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Models, Biological; Neoplasms; Treatment Outcome; Vidarabine Phosphate; Xenograft Model Antitumor Assays | 2009 |
Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.
Topics: Adenocarcinoma; Arabinonucleotides; Drug Evaluation; Female; Humans; Kinetics; Lung Neoplasms; Male; Neoplasms; Vidarabine; Vidarabine Phosphate | 1984 |
Effects on human peripheral lymphocytes of in vivo administration of 9-beta-D-arabinofuranosyl-2-fluoroadenine-5'-monophosphate (NSC 312887), a new purine antimetabolite.
Topics: Adult; Aged; Arabinonucleotides; B-Lymphocytes; Drug Evaluation; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Leukocyte Count; Leukocytes; Male; Middle Aged; Neoplasms; T-Lymphocytes; Vidarabine Phosphate | 1984 |
Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Drug Evaluation; Humans; Injections, Intravenous; Multivariate Analysis; Neoplasms; Vidarabine; Vidarabine Phosphate | 1990 |
Phase I clinical trial of fludarabine phosphate (F-ara-AMP).
Topics: Adult; Aged; Arabinonucleotides; Bone Marrow; Drug Evaluation; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Thrombocytopenia; Vidarabine Phosphate | 1985 |
Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleotides; Drug Administration Schedule; Drug Evaluation; Female; Humans; Male; Middle Aged; Neoplasms; Nervous System; Vidarabine Phosphate | 1988 |